Skip to main content
37°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Verve Therapeutics Inc
(NQ:
VERV
)
6.580
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
6.580
Bid (Size)
6.450 (1)
Ask (Size)
6.820 (1)
Prev. Close
6.580
Today's Range
6.580 - 6.580
52wk Range
6.420 - 21.42
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
12 Health Care Stocks Moving In Tuesday's After-Market Session
April 23, 2024
Via
Benzinga
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
April 11, 2024
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
Performance
YTD
-53.00%
-53.00%
1 Month
-50.00%
-50.00%
3 Month
-42.58%
-42.58%
6 Month
-29.63%
-29.63%
1 Year
-58.14%
-58.14%
More News
Read More
After a Serious Setback, Is Verve Therapeutics a Buy?
April 06, 2024
Via
The Motley Fool
Cathie Wood's Ark Invest Sheds $6.4M Worth Of Coinbase Shares Despite Positive Market Movements, Analyst Upgrade
April 04, 2024
Via
Benzinga
Cathie Wood's Ark Invest Buys More Shares Of This Meta Platforms Competitor
April 03, 2024
Via
Benzinga
Verve Therapeutics: Q4 Earnings Insights
February 27, 2024
Via
Benzinga
Nasdaq Down Over 1%; VivoPower International Shares Spike Higher
April 02, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Dow Stumbles, Heads For Worst Day Since February
April 02, 2024
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
April 02, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
April 02, 2024
Via
Benzinga
Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol
April 02, 2024
Via
Benzinga
Crude Oil Surges Over 1%; US Factory Orders Increase In February
April 02, 2024
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
April 02, 2024
From
Schall Law
Via
GlobeNewswire
Verve Plummets To Record Low After Its Gene-Editing Drug Causes Side Effects
April 02, 2024
Via
Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 02, 2024
Via
Benzinga
Verve Therapeutics Announces Updates on its PCSK9 Program
April 02, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 28, 2024
From
Verve Therapeutics
Via
GlobeNewswire
3 Stocks That Could Be the Next Big Thing in Gene Editing
March 21, 2024
Via
InvestorPlace
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 01, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug
February 27, 2024
Via
Investor's Business Daily
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Verve Therapeutics
Via
GlobeNewswire
3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential
February 19, 2024
Via
InvestorPlace
3 Gene Editing Stocks With Unprecedented Surge Potential
February 13, 2024
Via
InvestorPlace
2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare
February 12, 2024
Via
The Motley Fool
Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 01, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.